Samrat Pharmachem (BOM:530125) ROCE %: -10.13% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530125 Samrat Pharmachem Ltd BOM:530125
63 GF Score
Price ₹247.85
GF Value ₹362.79
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Samrat Pharmachem ROCE %?

Samrat Pharmachem BOM:530125 -0.04% 63 ROCE % is -10.13% as of Mar. 2026. GuruFocus rates BOM:530125 with a GF Score™ of 63/100 and a GF Value™ of ₹362.79 (Significantly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Samrat Pharmachem's annualized ROCE % for the quarter that ended in Mar. 2026 was -10.13%.

Samrat Pharmachem  (BOM:530125) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Samrat Pharmachem ROCE % Related Terms

Samrat Pharmachem ROCE % Historical Data

* Premium members only.

The historical data trend for Samrat Pharmachem's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Samrat Pharmachem ROCE % Chart

Samrat Pharmachem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.96 42.39 4.77 15.39 -2.88

Samrat Pharmachem Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 3.59 -2.78 -2.49 -10.13
BOM:530125
63GF Score
Samrat Pharmachem Ltd BOM:530125
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Samrat Pharmachem ROCE % Calculation

Samrat Pharmachem's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-20.257/( ( (1214.941 - 495.828) + (1244.157 - 558.249) )/ 2 )
=-20.257/( (719.113+685.908)/ 2 )
=-20.257/702.5105
=-2.88 %

Samrat Pharmachem's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-69.472/( ( (0 - 0) + (1244.157 - 558.249) )/ 1 )
=-69.472/( ( 0 + 685.908 )/ 1 )
=-69.472/685.908
=-10.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -10.13% mean?
Samrat Pharmachem (BOM:530125) has a ROCE % of -10.13% as of Mar. 2026.
Is Samrat Pharmachem's ROCE % too high?
Samrat Pharmachem's current ROCE % is -10.13%. Overall, Samrat Pharmachem has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's ROCE % compare to DOW?
Samrat Pharmachem's ROCE % of -10.13% can be compared against companies in the Chemicals industry. The industry median ROCE % is 6.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Chemicals company?
The median ROCE % among Chemicals companies is 6.57, based on 1,588 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median ROCE % is 6.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current ROCE % is -10.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.79, compared to a current price of ₹247.85 — trading 31.7% below its estimated fair value. The current ROCE % is -10.13%. Samrat Pharmachem's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current ROCE % is -10.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?

Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued. The current stock price of ₹247.85 is trading 31.7% below its estimated GF Value™ of ₹362.79. GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.

Key valuation signals for BOM:530125:

  • ROCE %: -10.13%
  • GF Value™: ₹362.79 vs. price of ₹247.85 (31.7% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Samrat Pharmachem Business Description

Address M. A. Road, 701/702, Business Square, Andheri (West), Mumbai, MH, IND, 400 058
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
63GF Score

Get the complete analysis for BOM:530125

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹247.85
Price
₹362.79
GF Value